About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NEOS
- Previous Close: $5.95
- 50 Day Moving Average: $5.74
- 200 Day Moving Average: $6.65
- 52-Week Range: $4.85 - $11.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.84
- P/E Growth: -0.01
- Market Cap: $95.56M
- Outstanding Shares: 16,060,000
- Beta: -0.92
- Net Margins: -1,013.17%
- Return on Equity: -144.74%
- Return on Assets: -64.00%
Companies Related to Neos Therapeutics:
- Debt-to-Equity Ratio: 3.68%
- Current Ratio: 3.36%
- Quick Ratio: 3.10%
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?
4 equities research analysts have issued 12-month price objectives for Neos Therapeutics' shares. Their forecasts range from $15.00 to $32.00. On average, they expect Neos Therapeutics' stock price to reach $25.33 in the next twelve months.
When will Neos Therapeutics announce their earnings?
Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.
Who owns Neos Therapeutics stock?
Neos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.19%), DSC Advisors L.P. (4.32%), Deerfield Management Co. (1.43%), State Street Corp (0.96%), Putnam Investments LLC (0.72%) and Russell Investments Group Ltd. (0.54%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell.
Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?
Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC and DSC Advisors L.P..
Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?
Neos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp and Franklin Resources Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell.
How do I buy Neos Therapeutics stock?
Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Neos Therapeutics stock cost?
One share of Neos Therapeutics stock can currently be purchased for approximately $5.95.